By Xiu Ying, Contributing Reporter
RIO DE JANEIRO, BRAZIL - The National Health Surveillance Agency (Anvisa) authorized the marketing of the first inhalable insulin in the country. The decision granting registration of the product was approved last Thursday, May 30th, and published this Monday, June 3rd, in the Diário Oficial da União (Federal Gazette).
Named Afrezza, the new insulin is sold in powder form, in capsules with three different types of dosage. The diabetic patient needs to insert the capsule into the inhaler and draw in the powder for use.
The substance reaches the lungs and is absorbed into . . .